



BerGenBio

Pareto Securities' Healthcare Conference

Introduction and Update Q2 2020

BerGenBio ASA
Jonas Lies vei 91, Bergen, 5009, Norway
www.bergenbio.com
IR contact: IR @bergenbio.com

3rd September 2020

Richard Godfrey, CEO

Forward Looking statements

Certain statements contained in this presentation constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and they can be identified by the use of forward-looking terminology, including the words "anticipate", "believe", "intend", "estimate", "expect", "will", "may", "should" and words of similar meaning. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. Accordingly, no assurance is given that such forward-looking statements will prove to have been correct. They speak only as at the date of the presentation and no representation or warranty, expressed or implied, is made by BerGenBio ASA or its affiliates ("BerGenBio"), or by any of their respective members, directors, officers

or employees that any of these forward-looking statements or forecasts will come to pass or that any forecast result will be achieved and you are cautioned not to place any undue influence on any forward-looking statement. BerGenBio is making no representation or warranty, expressed or implied, as to the accuracy, reliability or completeness of this presentation, and neither BerGenBio nor any of its directors, officers or employees will have any liability to you or any other person resulting from the use of this presentation.

Copyright of all published material, including photographs, drawings and images in this presentation remain with BerGenBio and relevant third parties, as appropriate. Consequently, no reproduction in any form of the presentation, or parts thereof, is permitted without the prior written permission, and only with appropriate acknowledgements.

BerGenBio corporate over view



World leaders in understanding AXL biology

AXL tyrosine kinase mediates aggressive disease: immune evasion, therapy resistance & metastatic cancer, fibrosis and viral infection

Selective AXL inhibitors have the potential to treat many serious unmet medical needs

Pipeline opportunities in multiple aggressive diseases



2 selective AXL inhibitors in clinical development

Bemcentinib (oral once a day pill)
Tilvestamab (mAb)

Bemcentinib broad Phase II program
Monotherapy and combos with CPI, targeted & chemo

Biomarker correlation, parallel CDx development

Bemcentinib clinical data points 2020:
AML (chemo-combo)
NSCLC (KEYTRUDA combo) **COVID19** (mono)



Resourced to deliver milestones


Listed on Oslo Børs: BGBIO

Clinical trial collaborations
Merck, UKRI, and leading academic centres EU & USA


45 staff at two locations:
HQ & R&D in Bergen, Norway;
Clinical Development in Oxford, UK

Cash Q2'20 NOK828m,

AXL drives aggressive disease



AXL Biology



- AXL mediates multiple survival mechanisms used by cancers:
 - Chemo drug resistance, immune evasion, metastasis
- AXL facilitates viral entry to host cells and reduces anti-viral immunity

- AXL a receptor tyrosine kinase that is important for regulating innate immune cells.¹
- AXL levels are elevated by cellular stress and is strongly associated with inflammatory diseases including cancer and fibrosis.²
- It functions as a homeostatic regulator in adult tissues and organ systems that are subject to continuous challenge and renewal throughout life – immune, nervous, vascular and reproductive
- AXL drives cancer progression, immune evasion, and resistance to targeted therapies.³
- AXL is a key suppressor of the type I interferon response and is targeted by viruses to block the anti-viral immunity.⁴
- AXL is used by several different enveloped viruses (e.g. Ebola, Zika) to enter cells.⁵


Very low expression under healthy physiological conditions

Elevated AXL signaling strongly associated with cancer progression, immune evasion, drug resistance and metastasis

AXL mediates viral entry to cells and dampening of viral immune response



¹Lemke Cold Spring Harb Perspect Biol 2013; ²Zagórska Nat Immunol 2014, Ludwig Cancer Res 2018, Espindola, Am J Respir Crit Care Med. 2018;³Gay, Br J Cancer 2013; ⁴Chen Nat Microbiol 2018; ⁵Moller-Tank Virology 2014;

AXL is a key survival mechanism 'hijacked' by aggressive cancers and drives drug resistance, immune-suppression & metastasis



AXL increases on immune cells and suppresses the innate immune response

- M1 to M2 macrophage polarisation¹
- Decreased antigen presentation by DCs²
- Prevent CD8+ T cell mediated cell death³
- Activates Treg cells



AXL increases on the tumor cell and causes cancer escape and survival


- AXL is a unique type I interferon (IFN) response checkpoint
- Acquired drug resistance
- Immune cell death resistant
- Metastasis

DC- dendritic cells Treg – Regulatory T Cell

⁶ 1.Ludvig et al Can Res, 2018; Davidsen et al., submitted 2.Kurowska-Stolarska et al Nature Comm 2017; Rothlin et al Cell 2007 3.Ludvig et al Can Res, 2018; Davidsen et al., submitted

AXL is targeted by enveloped viruses to enter cells and dampen the viral immune response

Enveloped viruses display phosphatidylserine that is recognized by GAS6, the AXL receptor ligand, that mediates viral entry through “apoptotic mimicry”.




Viral-mediated AXL receptor activation dampens type I interferon responses, a key anti-viral defence mechanism for all cells


bemcentinib blocks AXL-dependent viral entry and enhances anti-viral interferon response

Bemcentinib potently inhibits SARS-CoV-2 infection of cells.¹

Bemcentininb



Bemcentinib, a first-in-class, potent, oral, highly selective AXL inhibitor




- ✓ Nanomolar in vitro potency ($IC_{50} = 150 \text{ nM}$)
- ✓ Uniquely selective for AXL
 - ✓ 50-100 fold selective *cf.* TAM kinases

- ✓ Manufacturing at increased scale for late stage regulatory filing
- ✓ Size 0 100mg HPMC capsules
- ✓ 3 years stability confirmed

- ✓ Once daily oral dosing
- ✓ Extensive Phase I & II experience
 - ✓ >300 patients
- ✓ Safety and tolerability profile supports use in combination with other drugs
- ✓ MOA is synergistic with other therapies, enhancing response

BerGenBio pipeline of sponsored clinical trials and near-term news flow




Candidate	Targeted Indication	Discovery	Preclinical	Phase I	Phase II	Registrational	Next expected news*
Bemcentinib monotherapy	>2L AML & MDS	Ph II safety and POC efficacy demonstrated in 39 patient trial					
Bemcentinib combination with LDAC	2L AML	Ph IIb Safety demonstrated, efficacy POC expansion study- 20 pts.					Q4'20 Update clinical & translational data ¹
Bemcentinib combination with Keytruda	2L NSCLC chemo refractory	Ph II POC efficacy demonstrated in 50 patient trial, end points met					Fully recruited
	2L NSCLC CPI refractory	Ph II stage 1, 13 pts. met ORR proof of concept end point Expansion 16 pts.					
	2L NSCLC CPI+chemo refractory	Ph II POC study ongoing 29 pts					Q4'20 Stage 1 preliminary interim clinical and translational data ^{3/4}
Bemcentinib monotherapy	Hospital COVID19 Patients	In set up stage					Q3'20, FPI
Tilvestamab (BGB149)	Phase I	Ph Ia HV SAD complete		Ph Ib MAD in set up			Q4'20 First patient In



* Increased uncertainty due to COVID crisis
 CPI – checkpoint inhibitor
 mOS – median overall survival

1 ASH – American Society of Hematology (Dec 5-8)
 2 Next Gen Immuno Oncology (25th June)
 3 SITC – Society of Immunotherapy of Cancer (Nov10-15)
 4 WCLC – World Congress of Lung Cancer (Jan 26-29 2021)

BerGenBio pipeline of Investigator Sponsored Trials (ISTs)

Candidate	Sponsor	Targeted Indication	Dimensions	Phase I	Phase II	Registrational	Next expected news*
Bemcentinib	Uni. Hospital Southampton / UKRI funded 	COVID19	Monotherapy	Randomised Phase II – 15 day treatment			Recruitment stop due to low incidence & funding cessation
	European MDS Cooperative Group	2L AML	Monotherapy	open-label, single-arm , phase II study.			Fully recruited.
		2L MDS	Monotherapy	open-label, single-arm , phase II study			Met Primary End Point of Overall Response Rate Full data in Q4'20 (ASH)
	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Recurrent Glioblastoma	Monotherapy	Ph I safety study			Interim analysis of bemcentinib levels at 5pts. YE'20
	University of Leicester  	Relapse Mesothelioma	+ pembrolizumab	Set up			FPI Q3'20
	Haukeland University Hospital	1L Metastatic Melanoma	+ pembrolizumab or +Dabrafenib/Trametinib	Randomised Phase II			Restart pending Biomarker Analysis Q3'20
	UT Southwestern Medical Center	2-4L Stage 4 NSCLC	+ docetaxel	Ph I safety study			Fully recruited YE'20 Confirm RP2D
	UT Southwestern Medical Center	1L metastatic or recurrent PDAC	+ Nab-paclitaxel+ Gemcitabine+ Cisplatin	Ph I safety study			



Ongoing trial



Completed Trial / stage

Bemcentinib clinical development in COVID19

To evaluate the efficacy and safety in hospitalized COVID19 patients

- ACCORD-2 trial
- BGBC020 trial in set up




BGBC020 – BerGenBio sponsored trial in COVID-19 patients

- COVID-19 pandemic remains ongoing – some slow down seen in countries with effective public health measures
 - 21m reported cases and more than 770,000 deaths worldwide
- Currently, no medication is recommended to treat COVID-19, and no cure is available.
- The FDA has granted emergency use authorization for the antiviral drug remdesivir to treat severe COVID-19.
- The U.S. National Institutes of Health recently recommended the corticosteroid dexamethasone for people with severe COVID-19 who require supplemental oxygen or mechanical ventilation.

BGBC020

- BerGenBio sponsored clinical trial COVID-19 patients
- Will be in a country of high COVID incidence
- Protocol will be very similar to the ACCORD trial protocol for bemcentinib
- Protocol will permit co-administration with remdesivir and dexamethasone
- Anticipate FPI September 2020.

Geographic distribution of 14-day cumulative number of reported COVID-19 cases per 100 000 population, worldwide, as of 17 August 2020



BGBC020 – BerGenBio sponsored trial in COVID-19 patients

WHO COVID19: 9-point category ordinal scale

	Setting	Severity	Supportive intervention	Bemcentinib (ACCORD 2)	Dexamethasone	Remdesivir
0	Uninfected	no clinical or virological evidence of infection				
1	Ambulatory	no limitation of activities				
2		limitation of activities				
3	Hospitalised	mild	no oxygen therapy	■	■	■
4			oxygen by mask or nasal prongs			
5		severe	noninvasive ventilation or high-flow oxygen			
6			intubation and mechanical ventilation			
7		ventilation and additional organ support – - vasopressors - renal replacement therapy (RRT) - extracorporeal membrane oxygenation (ECMO)				
8		Death				

Endpoints:

- **Time to clinical improvement of at least 2 points** (from randomisation) of patient's stage 3, 4 or 5 on a 9-point category ordinal scale, or live discharge from the hospital, whichever comes first

9-Point Category Ordinal Scale:

0. Uninfected, no clinical or virological evidence of infection
1. Ambulatory, no limitation of activities
2. Ambulatory, limitation of activities
- 3. Hospitalised – mild disease, no oxygen therapy**
- 4. Hospitalised – mild disease, oxygen by mask or nasal prongs**
- 5. Hospitalised – severe disease, noninvasive ventilation or high flow oxygen**
6. Hospitalised – severe disease, intubation and mechanical ventilation
7. Hospitalised – severe disease, ventilation and additional organ support – pressors, renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO)
8. Death

Bemcentinib clinical development in Acute Myeloid Leukemia (AML) and Myelodysplastic syndromes (MDS)

Phase I/II open label, multi centre international trials to evaluate safety and efficacy

BGBC003

- monotherapy in r/r patients AML or MDS ✓
- combination with low-dose cytarabine (LDAC) in 1L newly diagnosed or r/r patients with AML ✓
- combination with LDAC in 2L relapsed patients with AML **Expansion On going**


BGBIL009 – BERGAMO Investigator Sponsored Trial

- Monotherapy in r/r AML or MDS patients ✓



Bemcentinib clinical development in Acute Myeloid Leukemia / Myeloid Dysplastic Syndrome elderly, r/r patients, with no approved SoC.

Phase I n=36

Cohort A: Single agent bemcentinib dose-finding in r/r AML/MDS 


Established safety, PK-PD, and recommended Phase 2 dose

Recommended Phase 2 dose of bemcentinib in AML or MDS is 400/200 mg as single agent OR in combination.


- Phase I monotherapy
- ✓ safety
 - ✓ efficacy
 - ✓ biomarker correlation

Phase II Expansion Cohorts

Cohort B1 n=14
Monotherapy AML

Cohort B2 n=16
Combination with LDAC in newly diagnosed or relapsed AML 

Cohort B5 expansion n=20
Combination with LDAC relapsed AML (ongoing)

Cohort B3 n=14
Combination with decitabine in ND or relapsed AML 

Cohort B4 n=14
Monotherapy MDS

- Phase II expansion cohorts
- ✓ safety in combination
 - ✓ efficacy in LDAC combination
 - ✓ biomarker correlation

- Cohort B5**
- ✓ Expand LDAC combo
 - ✓ Anticipate read out ASH '20
 - ✓ Guide registration path

BGBIL009 / NCT03824080 (BERGAMO study)

- A phase II study evaluating the efficacy and safety of Bemcentinib in patients with MDS or AML failing standard of care therapy
- MET PRIMARY END POINT

- Investigator Sponsored Trial: EMSCO
- Chief Investigator : Uwe Platzbecker, MD, Leipzig University Hospital, Germany
- Open-label, multi-centre phase II trial of 45 patients with high risk MDS or AML who have failed or are refractory to hypomethylating agent treatment
 - Study Rationale: Poor prognosis / limited treatment options – mOS 5.6m after failing HMA for HR-MDS¹
 - Bemcentinib monotherapy standard dosing
- End Points:
 - Primary: Overall response rate assessed in week 17 (beginning of cycle 5)
 - Secondary: Toxicity, OS, PFS, TTF, DoR, BOR
 - Exploratory endpoint: Translational project evaluating the role of potential biomarkers, e.g. Axl/Gas6
- Full data to be disclosed at upcoming scientific / medical congress

Bemcentinib clinical development in Non Small Cell Lung Cancer (NSCLC)

Objective: to improve the effectiveness of immune check point inhibitor (CPI) (pembrolizumab/Keytruda) refractory NSCLC patients, with a well tolerated, effective, and convenient drug

Chemotherapy refractory patients




CPI +/- chemotherapy refractory patients **On going**

CPI + Chemotherapy refractory patients **On going**




Bemcentinib + KEYTRUDA in refractory/relapsed NSCLC

Phase II Study Design




Composite AXL (cAXL) status defined by presence of AXL on membranes of tumor & immune cells in tumour micro environment

Example of high AXL expression on tumour cells: cAXL status of this patient is positive



Example of tumour with a high number of AXL positive immune cells: cAXL status of this patient is positive



- Arrows directed at examples of positively-stained **tumour** and **immune** cell, respectively
- Both patients experienced significant tumour shrinkage on bemcentinib + pembrolizumab treatment combination



Cohort A: stage 1 + 2 data (n=50)

NSCLC patients previously treated with a platinum containing chemotherapy

50% of patients are cAXL +ve :

- ✓ - mOS 17.3months : 140% greater in cAXL +ve patients
- ✓ - mPFS: 442% greater in cAXL +ve patients
- ✓ - ORR cAXL +ve patients 5 X cAXL -ve patients
- ✓ - 73% Clinical Benefit Rate in cAXL +ve patients
- ✓ - independent of PD-L1 status


Change in tumour size from baseline in cAXL-evaluable patients only



Enhanced survival in cAXL +ve patients with addition of bemcentinib to pembrolizumab

AXL is an adverse prognostic biomarker

mPFS 8.4 months in cAXL+ patients




Cohort	mOS	12-mo OS
Cohort A – cAXL +ve pts**	17.3 mo*	79%
Cohort A – cAXL -ve pts**	12.4 mo*	60%
BGB Cohort A – all pts**	12.6 mo*	64%* (up to 67%)
CheckMate-057 (Opdivo)	12.2 mo	51%
KEYNOTE-010 (Keytruda)	10.4 mo	43.2%

*OS data still maturing, current calculation (cut-off survival: 28-May-2020)
 **pts who have been on study treatment for at least 1 cycle (n=42)


- 4-fold improvement in PFS in cAXL +ve vs. cAXL -ve patients.
- 12 mo OS in cAXL positive patients 79% vs 60% in cAXL negative patients
- Clinical benefit reflected in mOS of cAXL +ve patients vs. cAXL -ve
- cAXL -ve patient survival data is comparable to historic controls

Cohort B:

NSCLC patients previously treated with a checkpoint inhibitor (PD-L1 or PD-1 inhibitor)



Time on treatment in patients evaluable for cAXL




+ cAXL positive
- cAXL negative

Previous immunotherapy (1 or 2L)
P: pembrolizumab; **A:** atezolizumab; **N:** nivolumab; **C:** cetrelimab; **I:** ipilumimab; **O:** other

Data cut-off: 17-April-2020

mPFS improvement in cAXL +ve patients



Finance Report


Q2, 2020



Key financial figures


(NOK million)	Q2 2020	Q2 2019	YTD 2020	YTD 2019	FY 2019
Operating revenues	0,0	0,0	0,0	8,7	8,9
Operating expenses	64,7	52,0	121,0	106,5	213,3
Operating profit (-loss)	-64,7	-52,0	-121,0	-97,8	-204,4
Profit (-loss) after tax	-67,3	-52,8	-115,8	-97,1	-199,3
Basic and diluted earnings (loss) per share (NOK)	-0,86	-0,95	-1,59	-1,76	-3,43
Net cash flow in the period	412,3	19,0	571,3	-35,2	-107,2
Cash burn operating activities	-50,0	-53,0	-109,1	-108,6	-186,7
Cash position end of period	828,4	324,4	828,4	324,4	253,6

Operating expenses Q2 2020 (YTD)



■ R&D ■ Administration

Operating profit (-loss) million NOK




- Well managed overhead costs.
- 73,49 % of operating expenses Q2 2020 (YTD 78.15%) is attributable to Research & Development activities.
- Organisation growth in preparation for late stage development (45 staff)

- NOK 7.5m of the operating loss in Q2 2020 is a P&L non cash option cost (increase in accruals for option and social and security tax on employee share option as a result of a positive development in the company's share price in the quarter). In Q2 2019 the option cost was negative with NOK 2.5 million.


Cash flow and cash position

Cash flow (million NOK)



- Cash flow from operating activities NOK -50m.
- Q2 cash flow include proceed from Private Placement in May raising gross NOK 500m.
- Quarterly average cash burn (Q219 – Q220) NOK 48.3m (USD 5.2m)

Cash position (million NOK)



- Cash position Q2 2020 NOK 828.4 million (USD 85.7m).
- Subsequent repair offering completed July 2020 not included, raising an additional NOK 20m (USD 2.1m).

Analyst coverage



H.C. Wainwright & Co

Joseph Pantginis

Telephone: +1 646 975 6968

E-mail: jpantginis@hcwresearch.com



Jones Trading

Soumit Roy

Telephone: +1 646 454 2714

E-mail: sroy@jonestrading.com



Arctic Securities

Pål Falck

Telephone: +47 229 37 229

E-mail: pal.falck@arctic.com

Sponsored research:



Trinity Delta

Mick Cooper, PhD

Telephone: +44 20 3637 5042

mcooper@trinitydelta.org



DNB Markets

Patrik Ling

Telephone: +46 8 473 48 43

E-mail: patrik.ling@dnb.se

Link to reports from Trinity Delta:

<https://www.bergenbio.com/investors/analyst-coverage/>

News Flow 2020



Expected Newsflow* 2020

Next-Gen
25th June
NSCLC
Bem + KEYTRUDA

SITC
10-15 Nov
NSCLC
Bem + KEYTRUDA

WCLC
26-29 Jan
NSCLC
Bem + KEYTRUDA

2020 | MAY | JUN | JUL | AUG | SEP | OCT | NOV | DEC | 2021

ASH
5-8 Dec
AML & MDS
Bem + LDAC
update

* Conditional on impact of global COVID crisis

ASH – American Society of Hematology (Dec 5-8)

Next Gen Immuno Oncology (25th June)

32 SITC – Society of Immunotherapy of Cancer (Nov10-15)

WCLC – World Congress of Lung Cancer (Jan 26-29 2021)